Orexin gene therapy restores the timing and maintenance of wakefulness in narcoleptic mice

Sleep

Volumn 36, Issue 8, 2013, Pages 1129-1138

  Kantor, Sandor ^a,b   Mochizuki, Takatoshi ^a   Lops, Stefan N ^a,c   Ko, Brian ^a   Clain, Elizabeth ^a   Clark, Erika ^a   Yamamoto, Mihoko ^a   Scammell, Thomas E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AAV orexin; Ataxin 3; Cataplexy; Gene therapy; Hypothalamus; Locomotor activity; Narcolepsy; Wake maintenance

Indexed keywords

ATAXIN 3; OREXIN; PARVOVIRUS VECTOR; RED FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AROUSAL; ARTICLE; BODY TEMPERATURE; BRAIN NERVE CELL; CATAPLEXY; CIRCADIAN RHYTHM; CONTROLLED STUDY; LOCOMOTION; MALE; MEDIOBASAL HYPOTHALAMUS; MOUSE; NARCOLEPSY; NONHUMAN; NONREM SLEEP; PRIORITY JOURNAL; PROTEIN EXPRESSION; REM SLEEP; SIGNAL TRANSDUCTION; SLEEP WAKING CYCLE; VIRAL GENE THERAPY; WAKEFULNESS;

AAV-OREXIN; ATAXIN-3; CATAPLEXY; GENE THERAPY; HYPOTHALAMUS; LOCOMOTOR ACTIVITY; NARCOLEPSY; WAKE MAINTENANCE;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, TRANSGENIC; NARCOLEPSY; NEUROPEPTIDES; NUCLEAR PROTEINS; POLYSOMNOGRAPHY; SLEEP; TRANSCRIPTION FACTORS; WAKEFULNESS;

EID: 84881152747     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.2870     Document Type: Article

References (50)

1. Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007;8: 373-99.
2. Fronczek R, Middelkoop HA, van Dijk JG, Lammers GJ. Focusing on vigilance instead of sleepiness in the assessment of narcolepsy: high sensitivity of the Sustained Attention to Response Task (SART). Sleep 2006;29: 187-91.
3. Broughton R, Ghanem Q, Hishikawa Y, Sugita Y, Nevsimalova S, Roth B. Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Can J Neurol Sci 1981;8: 299-304.
4. Findley LJ, Suratt PM, Dinges DF. Time-on-task decrements in "steer clear" performance of patients with sleep apnea and narcolepsy. Sleep 1999;22: 804-9.
5. Ozaki A, Inoue Y, Nakajima T, et al. Health-related quality of life among drug-naive patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time. J Clin Sleep Med 2008;4: 572-8.
6. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 2003;53: 154-66.
7. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6: 991-7.
8. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27: 469-74.
9. Crocker A, Espana RA, Papadopoulou M, et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005;65: 1184-8.
10. Bourgin P, Huitron-Resendiz S, Spier AD, et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 2000;20: 7760-5.
11. Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007;450: 420-4.
12. Mochizuki T, Arrigoni E, Marcus JN, et al. Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. Proc Natl Acad Sci U S A 2011;108: 4471-6.
13. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98: 437-51.
14. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001;30: 345-54.
15. Espana RA, McCormack SL, Mochizuki T, Scammell TE. Running promotes wakefulness and increases cataplexy in orexin knockout mice. Sleep 2007;30: 1417-25.
16. Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE. Sleep state switching. Neuron 2010;68: 1023-42.
17. Mitler MM, Hayduk R. Benefits and risks of pharmacotherapy for narcolepsy. Drug Saf 2002;25: 791-809.
18. Tal J. Adeno-associated virus-based vectors in gene therapy. J Biomed Sci 2000;7: 279-91.
19. Scammell TE, Arrigoni E, Thompson MA, Ronan PJ, Saper CB, Greene RW. Focal deletion of the adenosine A1 receptor in adult mice using an adeno-associated viral vector. J Neurosci 2003;23: 5762-70.
20. Griffey M, Macauley SL, Ogilvie JM, Sands MS. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol Ther 2005;12: 413-21.
21. Pawlyk BS, Smith AJ, Buch PK, et al. Gene replacement therapy rescues photoreceptor degeneration in a murine model of Leber congenital amaurosis lacking RPGRIP. Invest Ophthalmol Vis Sci 2005;46: 3039-45.
22. High KA, Aubourg P. rAAV human trial experience. Methods Mol Biol 2011;807: 429-57.
23. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004;101: 4649-54.
24. Kantor S, Mochizuki T, Janisiewicz AM, Clark E, Nishino S, Scammell TE. Orexin neurons are necessary for the circadian control of REM sleep. Sleep 2009;32: 1127-34.
25. Scammell TE, Willie JT, Guilleminault C, Siegel JM. A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 2009;32: 111-6.
26. Fujiki N, Cheng T, Yoshino F, Nishino S. Specificity of direct transitions from wake to REM sleep in orexin/ataxin-3 narcoleptic mice. Sleep 2006;29:A225.
27. Yoshida K, McCormack S, Espana RA, Crocker A, Scammell TE. Afferents to the orexin neurons of the rat brain. J Comp Neurol 2006;494: 845-61.
28. Liu M, Blanco-Centurion C, Konadhode R, et al. Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice. J Neurosci 2011;31: 6028-40.
29. Trachsel L, Tobler I, Achermann P, Borbely AA. Sleep continuity and the REM-nonREM cycle in the rat under baseline conditions and after sleep deprivation. Physiol Behav 1991;49: 575-80.
30. Franken P, Malafosse A, Tafti M. Genetic determinants of sleep regulation in inbred mice. Sleep 1999;22: 155-69.
31. Mochizuki T, Crocker A, McCormack S, Yanagisawa M, Sakurai T, Scammell TE. Behavioral state instability in orexin knock-out mice. J Neurosci 2004;24: 6291-300.
32. Edgar DM, Dement WC, Fuller CA. Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. J Neurosci 1993;13: 1065-79.
33. Xu B, Goulding EH, Zang K, et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 2003;6: 736-42.
34. Mochizuki T, Klerman EB, Sakurai T, Scammell TE. Elevated body temperature during sleep in orexin knockout mice. Am J Physiol Regul Integr Comp Physiol 2006;291:R533-40.
35. Lavie P. REM periodicity under ultrashort sleep/wake cycle in narcoleptic patients. Can J Psychol 1991;45: 185-93.
36. Dantz B, Edgar DM, Dement WC. Circadian rhythms in narcolepsy: studies on a 90 minute day. Electroencephalogr Clin Neurophysiol 1994;90: 24-35.
37. Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci 1995;15: 3526-38.
38. Wurts SW, Edgar DM. Circadian and homeostatic control of rapid eye movement (REM) sleep: promotion of REM tendency by the suprachiasmatic nucleus. J Neurosci 2000;20: 4300-10.
39. Lee ML, Swanson BE, de la Iglesia HO. Circadian timing of REM sleep is coupled to an oscillator within the dorsomedial suprachiasmatic nucleus. Curr Biol 2009;19: 848-52.
40. Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000;12: 726-30.
41. Espana RA, Baldo BA, Kelley AE, Berridge CW. Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. Neuroscience 2001;106: 699-715.
42. Liu M, Thankachan S, Kaur S, et al. Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci 2008;28: 1382-93.
43. Okuro M, Fujiki N, Kotorii N, Ishimaru Y, Sokoloff P, Nishino S. Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice. Sleep 2010;33: 930-42.
44. Yoshida Y, Fujiki N, Nakajima T, et al. Fluctuation of extracellular hypocretin- 1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 2001;14: 1075-81.
45. Blanco-Centurion C, Liu M, Konadhode R, Pelluru D, Shiromani PJ. Effects of orexin gene transfer in the dorsolateral pons in orexin knockout mice. Sleep 2013;36: 31-40.
46. Makela KA, Wigren HK, Zant JC, et al. Characterization of sleep-wake patterns in a novel transgenic mouse line overexpressing human preproorexin/ hypocretin. Acta Physiol (Oxf) 2010;198: 237-49.
47. Zhang S, Zeitzer JM, Sakurai T, Nishino S, Mignot E. Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy. J Physiol 2007;581: 649-63.
48. Willie JT, Takahira H, Shibahara M, et al. Ectopic overexpression of orexin alters sleep/wakefulness states and muscle tone regulation during REM sleep in mice. J Mol Neurosci 2011;43: 155-61.
49. Mandel RJ, Manfredsson FP, Foust KD, et al. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 2006;13: 463-83.
50. Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. 2nd ed. San Diego: Academic Press, 2001.